Business

RAMSAY SANTE : Half-year results at the end of December 2025

PRESS RELEASE Paris, 25th February 2026 Half-year results at the end of December 2025 Quality offering driving revenue growth, with continued efficiency supporting operational profitability Public funding to mitigate cost inflation still a challenge Group Revenue up 3.3% to €2.6bn (+2.3% LFL) from (i) a recognized quality offering driving volumes in France and (ii) strong fundamentals in the Nordics, with positive price indexation and favourable currency effects.Group EBITDA stable at €285m (11.

articleRamsay Generale De Sante SaFebruary 25, 202624/company/ramsay-generale-de-sante-sa/news/ramsay-sante-half-year-results-at-the-end-of-december-2025
RAMSAY SANTE : Half-year results at the end of December 2025

About this update from Ramsay Generale De Sante Sa

[{"type":"image","alt":"RAMSAY SANTE","displaySize":"","headline":null,"caption":"RAMSAY SANTE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":288,"url":"https://media.zenfs.com/en/globenewswire.com/959bad3a6a10a6a66985b8a318e1818f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OqHn2cm.eQhr7uXoVH6nZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQwMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/959bad3a6a10a6a66985b8a318e1818f","width":300,"height":288}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"Paris, 25th February 2026","length":25,"tagName":"p"},{"type":"text","content":"Half-year results at the end of December 2025","length":45,"tagName":"p"},{"type":"text","content":"Quality offering driving revenue growth, with continued efficiency supporting operational profitability Public funding to mitigate cost inflation still a challenge","length":165,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Group Revenue up 3.3% to €2.6bn (+2.3% LFL) from (i) a recognized quality offering driving volumes in France and (ii) strong fundamentals in the Nordics, with positive price indexation and favourable currency effects.","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Group EBITDA stable at €285m (11.0% margin), with sustained operating cost control, performance and efficiency offsetting (i) the anticipated €20m shortfall in French revenue guarantee and (ii) the insufficient public funding of tariff indexation versus cost inflation gap.","length":273,"tagName":"p"}]},{"val":[{"type":"text","content":"Net loss (group share) reduced to €(35)m, a €8m year-on-year improvement reflecting lower financing costs following recent debt refinancing.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Net cash flow from operating activities was €122.6m, down €47.3m year-on-year, notably due to the expected working capital impact from the repayment of remaining French State advances.","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Net financial debt amounted to €3,757m, including €1,845m of restated (pre-IFRS16) net debt.","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Pre-IFRS16 restated net leverage improved to 5.3x (vs. 5.4x as of December 2024).","length":81,"tagName":"p"}]}],"tagNam...

More updates from Ramsay Generale De Sante Sa

financial debtconsolidated financial statementsRamsay SantéNet cash flowRamsay Health Care LimitedFrance